Modality
siRNA
MOA
PD-1i
Target
BET
Pathway
Innate Imm
RBCrohn'sSCLC
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
Sep 2021
→ May 2029
Phase 1Current
NCT03804662
235 pts·SCLC
2021-10→TBD·Recruiting
NCT04786781
1,177 pts·RB
2021-09→2029-05·Terminated
1,412 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-123.1y awayInterim· RB
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Termina…
P1
Recruit…
Catalysts
Interim
2029-05-12 · 3.1y away
RB
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03804662 | Phase 1 | SCLC | Recruiting | 235 | EASI-75 |
| NCT04786781 | Phase 1 | RB | Terminated | 1177 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| 207-5197 | Samsung Biologics | Approved | BET | |
| ILM-5680 | Illumina | Phase 2 | BET |